Kyntheum
brodalumab · LEO Pharma A/S
AUTHORISED IN THE EUWhat Kyntheum is used for
Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Kyntheum
- Active substance
- brodalumab
- Disease area
- Psoriasis
- Medicine group
- Immunosuppressants
- ATC code
- L04AC12
- Marketing authorisation holder
- LEO Pharma A/S
- Authorised in the EU since
- 2017
Official information
In the USA
Same active substance: Siliq
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kyntheum used for?
Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
What is the active substance in Kyntheum?
Kyntheum contains brodalumab.
Who makes Kyntheum?
The EU marketing authorisation holder is LEO Pharma A/S.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU